Related Experiment Videos
[Hypertrophic cardiomyopathy: a genetically-carried heart disease]
W G van Dockum1, P A F M Doevendans, A C van Rossum
1Academisch Ziekenhuis Vrije Universiteit, afd. Cardiologie, Postbus 7057, 1007 MB Amsterdam. wg.vandockum@vumc.nl
Insights
Hypertrophic cardiomyopathy (HCM) is an inherited heart muscle disease affecting 1 in 500 people. Early detection through genotyping is crucial for identifying predisposition and preventing sudden cardiac death.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Context:
- Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart condition characterized by left ventricular hypertrophy.
- Affecting approximately 1 in 500 individuals, HCM exhibits diverse clinical and morphological manifestations.
- The disease arises from mutations in genes encoding sarcomere proteins essential for cardiac muscle contraction.
Purpose:
- To provide a comprehensive overview of Hypertrophic Cardiomyopathy (HCM).
- To detail diagnostic modalities including electrocardiography, echocardiography, and cardiac MRI.
- To outline current and emerging therapeutic strategies for HCM management.
Summary:
- HCM involves abnormal thickening of the heart muscle, often inherited and linked to sarcomere gene mutations.
- Diagnosis relies on imaging techniques and genetic testing for early identification.
- Treatment options range from medication to surgical and non-surgical interventions, including implantable cardioverter-defibrillators for high-risk patients.
Impact:
- Facilitates early diagnosis and risk stratification for Hypertrophic Cardiomyopathy.
- Informs therapeutic strategies aimed at improving diastolic filling, ventricular function, and preventing sudden cardiac death.
- Highlights the critical role of genotyping in identifying individuals predisposed to HCM.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a cardiac muscle disease with characteristic (mostly asymmetrically distributed) hypertrophy of a non-dilated left ventricle in the absence of another cardiac or systemic disease that can cause left ventricle hypertrophy. The prevalence of HCM in the general population is estimated to be 1 in 500 persons. It is an inheritable disease of the heart with a heterogeneous expression and a great diversity of morphological, functional and clinical features. The genes involved code for components of a large protein complex ('the sarcomere'), which ensures the contraction of the cardiac muscle. Electrocardiography, echocardiography and cardiac MRI play a role in the diagnosis. Medicinal treatment can improve the diastolic filling and the ventricle function. In addition to this there are surgical and non-surgical possibilities for myocardial reduction. For patients with life-threatening arrhythmias and for the primary prevention of sudden death for high-risk patients, an internally implantable cardioverter-defibrillator is indicated. The early detection of patients with a predisposition for HCM is only possible by means of genotyping.